Regulatory Disclosure Details

Krsnaa Diagnostics Ltd (BSE Scrip Code: 543328, NSE Symbol: KRSNAA) submitted a regulatory filing to BSE Limited and National Stock Exchange of India Limited on November 02, 2026 (Ref. No.: KDL/SE/063/2026-27). The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, containing the company's unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026.

Financial Performance Highlights

Quarterly Performance (Q2 FY2027 vs Q2 FY2026)

  • Revenue from Operations: ₹2,710 million (32% YoY increase from ₹2,060 million)
  • EBITDA: ₹719 million (vs ₹602 million in Q2 FY2026)
  • EBITDA Margin: 27% (vs 29% in Q2 FY2026)
  • Profit After Tax (PAT): ₹246 million (vs ₹239 million in Q2 FY2026)
  • PAT Margin: 9% (vs 12% in Q2 FY2026)

Half-Yearly Performance (H1 FY2027 vs H1 FY2026)

  • Revenue from Operations: ₹5,065 million (27% YoY increase from ₹3,990 million)
  • EBITDA: ₹1,307 million (vs ₹1,126 million in H1 FY2026)
  • EBITDA Margin: 26% (vs 28% in H1 FY2026)
  • Profit After Tax (PAT): ₹411 million (vs ₹445 million in H1 FY2026)
  • PAT Margin: 8% (vs 11% in H1 FY2026)

The moderation in PAT during H1 FY2027 was primarily attributable to upfront expenditure towards the Rajasthan project, with the associated benefits expected to accrue in the coming quarters.

Business Segment Performance

Retail Business

  • Retail revenue grew 35% YoY to ₹235 million
  • Patient volumes increased 45% YoY
  • Test volumes grew 48% YoY
  • Retail segment contributed approximately 9% of overall revenue
  • Supported by asset-light network of franchisees, business associates, referral centres and strategic alliances

Operational Capabilities

  • Over 350 radiologists supporting radiology operations
  • Teleradiology capabilities across X-ray, CT and MRI
  • 57 NABL-accredited pathology laboratories
  • 75 NABH-accredited radiology centres
  • Operations across 19 states and Union Territories
  • More than 8,400+ touchpoints nationwide

Management Commentary

Mr. Yash Mutha, Managing Director: "Q2 FY27 reflects the continued growth of our diagnostic platform, supported by our established business and contributions from newly operationalized projects. Our focus remains on strengthening our existing PPP presence, capitalizing available opportunity in existing and untapped geographies and focus on accelerating cash business and building retail diagnostics as a complementary growth engine. We are also expanding specialized diagnostic offerings and exploring technology-led opportunities to enhance the reach and efficiency of our services."

Mr. Mitesh Dave, Group Chief Executive Officer: "Our focus during the quarter remained on execution and improving utilization across our expanding network. We are seeing encouraging traction in retail, with healthy growth in patient and test volumes. Alongside this, we continue to strengthen our radiology and pathology capabilities in an integrated manner. As our newer projects mature, we remain focused on improving operational efficiency and delivering a better patient experience."

Company Overview

Krsnaa Diagnostics Ltd is described as "one of India's leading integrated diagnostic service providers" with a differentiated diagnostic services provider across Radiology and Pathology. The company operates an integrated diagnostic, technology and logistics platform with a guiding philosophy of "Let's Do Good…".

Forward-Looking Statements

The release contains a safe harbor statement noting that it may contain forward-looking statements based on management's current expectations and beliefs, and that actual results may differ materially due to economic, business, regulatory, competitive and other risks. Krsnaa Diagnostics assumes no obligation to update such statements.